Research programme: smooth muscle myosin inhibitors - Cytokinetics
Alternative Names: CK-2018448; CK-2018509; CK-2018571; CK-2019165; Smooth muscle contractility programme - CytokineticsLatest Information Update: 04 Nov 2017
At a glance
- Originator Cytokinetics
- Class Small molecules
- Mechanism of Action Myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Hypertension; Pulmonary arterial hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation, Inhalant)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation, Inhalant)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in USA (Inhalation, Inhalant)